Clinical Surgical Oncology最新文献

{"title":"The long-term outcomes of metachronous tumors for non-small cell lung cancer","authors":"Celalettin Kocaturk ,&nbsp;Cem Emrah Kalafat ,&nbsp;Celal Bugra Sezen ,&nbsp;Mustafa Vedat Dogru ,&nbsp;Levent Cansever ,&nbsp;Muzaffer Metin ,&nbsp;Mehmet Ali Bedirhan","doi":"10.1016/j.cson.2024.100035","DOIUrl":"https://doi.org/10.1016/j.cson.2024.100035","url":null,"abstract":"<div><h3>Background</h3><p>We aimed to identify prognostic factors for mortality and survival in patients operated on for metachronous primary lung cancer (MPLC).</p></div><div><h3>Materials and methods</h3><p>The data of 67 non-small cell lung cancer patients with MPLC, diagnosed and operated upon between January 2000 and December 2015, were retrospectively analyzed.</p></div><div><h3>Results</h3><p>Of the 67 included patients, 63 (94%) were male and 4 (6%) were female. The overall survival rate after second surgery was 53.6% at 5 years and 34.1% at 10 years. The mean survival time was 64 months (95% confidence interval: 35–92 months). Adjuvant treatment improved survival (p ​= ​0.039). Although the survival of grade N0 and N1 patients did not differ, four grade N2 patients exhibited poor survival (p ​= ​0.02). Cox's regression analysis revealed that grade N2 disease decreased survival 5.3- fold, the absence of adjuvant treatment decreased survival 2 fold and pT4 grade decreased survival 3.4 fold.</p></div><div><h3>Conclusions</h3><p>New lung tumors may be detected during follow-up of lung cancer patients who have been definitively treated. In such cases, if extrapulmonary metastases and N2 lymphatic involvement are absent, there is no recurrence in the surgical margins of the first operation, and there is only one new tumor, we suggest that surgical treatment should be initially chosen for patients with adequate cardiopulmonary reserves regardless of the time of appearance of the second tumor, whether or not the histopathological type is the same as that of the first tumor.</p></div>","PeriodicalId":100278,"journal":{"name":"Clinical Surgical Oncology","volume":"3 1","pages":"Article 100035"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2773160X24000035/pdfft?md5=88aaf5b8d7fea618ca4f1b4fb9e6b82e&pid=1-s2.0-S2773160X24000035-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140122976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feeding Jejunostomy in Pancreatico-Duodenectomy patients: Is it important","authors":"Ahmed Mohamed Abdelaziz Hassan ,&nbsp;Hesham A. Elmeligy ,&nbsp;Magdy Elsebae ,&nbsp;Mohamed Abdo ,&nbsp;Ahmed M. Azzam ,&nbsp;Mahmoud Rady","doi":"10.1016/j.cson.2024.100038","DOIUrl":"https://doi.org/10.1016/j.cson.2024.100038","url":null,"abstract":"<div><h3>Background</h3><p>During a pancreaticoduodenectomy, Feeding Jejunostomy (FJ) is frequently placed to improve postoperative nutrition. Our aim is to ascertain the effects of the FJ tube after pancreaticoduodenectomy.</p></div><div><h3>Methods</h3><p>Prospective analysis was performed on all patients who underwent concurrent FJ after pancreaticoduodenectomy (Whipples surgery) between 2022 and 2023. On POD 1, FJ feeds were frequently initiated. After the patient had taken enough oral feeds, the jejunostomy feeds were stopped. Frequency and mean were used to represent the data.</p></div><div><h3>Results</h3><p>A total of 48 patients underwent pancreaticoduodenectomy with concomitant FJ. A total of 35 (72.9%) were men and the mean age was 49.2 years. The majority (28, 58.3 %) of these patients had cancer head of the pancreas as an indication for surgery. Only 13 out of 48 (27%) patients required nutrition supplementation through FJ on POD 10. Only 1 out of 48 (2%) patients required FJ feeds on POD 30. None of these patients had tube-related complications in the 30-day postoperative period. There was a single FJ-related mortality in the 30-day postoperative period due to pulmonary embolism. The patients, who required prolonged FJ feeds had grade C pancreatic leaks, delayed gastric emptying, and surgical site infection.</p></div><div><h3>Conclusion</h3><p>The routine use of concurrent FJ in patients undergoing pancreaticoduodenectomy has a good outcome, especially for those who require prolonged postoperative nutritional supplementation because of grade c pancreatic leak and delayed gastric emptying.</p></div>","PeriodicalId":100278,"journal":{"name":"Clinical Surgical Oncology","volume":"3 1","pages":"Article 100038"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2773160X24000060/pdfft?md5=ce107e4945998100e18df0061588be08&pid=1-s2.0-S2773160X24000060-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140095958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of preoperative subcutaneous adipose, visceral adipose and skeletal muscle on the outcomes of the oldest-old colorectal cancer patients after surgery","authors":"Jinxin Shi ,&nbsp;Jian Cui ,&nbsp;Wenrui Xu ,&nbsp;Zhexue Wang ,&nbsp;Junge Bai ,&nbsp;Zijian Li ,&nbsp;Fuhai Ma ,&nbsp;Tianming Ma ,&nbsp;Ju Cui ,&nbsp;Guoju Wu ,&nbsp;Gang Zhao ,&nbsp;Qi An","doi":"10.1016/j.cson.2024.100036","DOIUrl":"https://doi.org/10.1016/j.cson.2024.100036","url":null,"abstract":"<div><h3>Background</h3><p>Colorectal cancer (CRC) is one of the most common tumors worldwide, with rising numbers of elderly patients affected. Nutritional status significantly influences tumor prognosis. We aimed to investigate the association of subcutaneous and visceral adipose tissue and skeletal muscle mass with the prognosis of the oldest-old patients with CRC, after surgery.</p></div><div><h3>Patients</h3><p>We retrospectively reviewed 210 patients &gt;75 years who underwent surgical treatment at the Department of Gastrointestinal Surgery, Beijing Hospital, between December 2010 and December 2020.</p></div><div><h3>Materials</h3><p>Subcutaneous adipose, visceral adipose, and skeletal muscle areas were measured using BMI_CT. The cut-off values of the CT measurements were then confirmed using receiver operating characteristic (ROC) curve analysis.</p></div><div><h3>Results</h3><p>Subcutaneous adipose tissue index (SATI), visceral adipose tissue index (VATI), and total adipose tissue index (TATI) were significantly associated with sex and BMI. Notably, the oldest-old CRC patients with high SATI, VATI, and TATI scores exhibited significantly higher rates of wound complications and reduced postoperative hospitalization durations. Intriguingly, patients with high VATI and TATI demonstrated significantly better 5-year Overall survival (OS), Cancer-specific survival (CSS), and Disease-free survival (DFS) than patients in the other groups. Similar results were observed in patients with a high visceral-to-subcutaneous fat ratio (VSR) and skeletal muscle index (SMI) scores.</p></div><div><h3>Conclusion</h3><p>Significantly improving skeletal muscle content while concurrently managing the total adipose content, especially visceral adipose tissue, may aid in extending the survival time of oldest-old patients with CRC after surgery.</p></div>","PeriodicalId":100278,"journal":{"name":"Clinical Surgical Oncology","volume":"3 1","pages":"Article 100036"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2773160X24000047/pdfft?md5=8581fda3ca25b541d05c5bba599d25e9&pid=1-s2.0-S2773160X24000047-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140122977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proposed classification of Langer’s arch and its clinical implication in regard to axillary dissection","authors":"Soumen Das ,&nbsp;Sidhartha Misra ,&nbsp;Kamalesh Rakshit ,&nbsp;Sandipan Purkait ,&nbsp;Rahul Agarwal","doi":"10.1016/j.cson.2024.100037","DOIUrl":"10.1016/j.cson.2024.100037","url":null,"abstract":"","PeriodicalId":100278,"journal":{"name":"Clinical Surgical Oncology","volume":"3 1","pages":"Article 100037"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2773160X24000059/pdfft?md5=673f7ad1a5145be238a32e76a16747ba&pid=1-s2.0-S2773160X24000059-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140092467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Surgery patterns and survival of T4N2 non-small cell lung cancer – A population-based analysis","authors":"Chenxi Zhang ,&nbsp;Meiqing Zhang ,&nbsp;Jingxuan Chen ,&nbsp;Xiyang Tang ,&nbsp;Jincan Zhang ,&nbsp;Congwen Zhuang ,&nbsp;Xiaofei Li ,&nbsp;Zhiyong Zeng ,&nbsp;Jinbo Zhao","doi":"10.1016/j.cson.2024.100034","DOIUrl":"10.1016/j.cson.2024.100034","url":null,"abstract":"<div><h3>Objectives</h3><p>Present study aims to explore the surgery patterns and survival of T4N2 non-small cell lung cancer (NSCLC) in real-world condition.</p></div><div><h3>Materials and methods</h3><p>Clinical stage T4N2 NSCLC patients in Surveillance, Epidemiology and End Result Program were extracted. Cox regression was used for calculation of hazard ratio (HR) and confidence interval (CI), and landmark analysis was used for survival test at different cut-off time points.</p></div><div><h3>Results</h3><p>There were 1445 eligible patients included, of which 306 patients received surgery alone, 390 patients received induction therapy, and 749 patients received adjuvant therapy. For resection types, 1210 patients received lobectomy and 235 received pneumonectomy. Among patient receiving induction therapy, the overall survival (OS) HRs of pneumonectomy at 1-year, 3-year, 5-year, and 8-year cut-off points were 1.330, 0.972, 1.231, and 1.332 (P ​= ​0.708, 0.972, 0.281 and 0.145), respectively, and cancer-specific survival (CSS) HRs at these landmark points were 2.386, 1.231, 1.455, and 1.480 (P ​= ​0.293, P ​= ​0.409, 0.059 and 0.056), respectively. Among patients receiving adjuvant therapy, the OS HRs of pneumonectomy at 1-year and 8-year cut-off points were 1.570 and 1.274 (P ​= ​0.050 and 0.087), respectively, and CSS HRs at these landmark points were 1.493 and 1.284 (P ​= ​0.096 and 0.094), respectively. Both OS and CSS of patients receiving lobectomy were superior than pneumonectomy at 3-year and 5-year in this cohort. For patients receiving surgery alone, pneumonectomy resulted in inferior survival than lobectomy at all cut-off points (all P ​&lt; ​0.05).</p></div><div><h3>Conclusions</h3><p>Surgery after induction therapy is still an optional choice for T4N2 NSCLC, and pneumonectomy should not be excluded from treatment strategy.</p></div>","PeriodicalId":100278,"journal":{"name":"Clinical Surgical Oncology","volume":"3 1","pages":"Article 100034"},"PeriodicalIF":0.0,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2773160X24000023/pdfft?md5=945e1c87a7cb804d2b5eddaec515798f&pid=1-s2.0-S2773160X24000023-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139816748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Surgery patterns and survival of T4N2 non-small cell lung cancer – A population-based analysis","authors":"Chenxi Zhang, Meiqing Zhang, Jingxuan Chen, Xiyang Tang, Jincan Zhang, Congwen Zhuang, Xiaofei Li, Zhiyong Zeng, Jinbo Zhao","doi":"10.1016/j.cson.2024.100034","DOIUrl":"https://doi.org/10.1016/j.cson.2024.100034","url":null,"abstract":"","PeriodicalId":100278,"journal":{"name":"Clinical Surgical Oncology","volume":"16 11","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139876491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pooled analysis of rhabdoid pancreatic carcinomas: Should they be resected?","authors":"Wiktoria I. Batog ,&nbsp;Philip McEntee ,&nbsp;Niall Swan ,&nbsp;Paul F. Ridgway","doi":"10.1016/j.cson.2024.100033","DOIUrl":"10.1016/j.cson.2024.100033","url":null,"abstract":"<div><h3>Background</h3><p>Pancreatic undifferentiated carcinomas with rhabdoid features (PUCR) are infrequent, yet incredibly aggressive neoplasms. Recent advances in the histopathological understanding of PUCR have been made, however the optimal treatment of PUCR remains unclear and the decision to operate on the neoplasm is left to the physicians own judgement. Most of the literature published on this neoplasm constitutes case reports and case series, therefore our aim is to present a pooled analysis including the up-to-date literature and elucidate whether surgical treatment is the finest choice for PUCR.</p></div><div><h3>Methods</h3><p>This pooled analysis compared the data from 9 articles and a case that presented to our unit, yielding 28 cases. Treatment modalities reported in the literature were noted, and the surgical and post-operative adjuvant chemotherapy and &gt;3month survival were screened for dependence using a Chi-square test.</p></div><div><h3>Results</h3><p>The patient's median survival following a surgical resection of the neoplasm was three months. 77.7% who were treated surgically died within one year following the surgery. The relationship between surgical resection and survival calculated using the chi-square is not significant (p-value: 0.261). The median survival of patients who received post-operative chemotherapy was 7 months. The relationship between the post-operative adjuvant chemotherapy and survival 3 months is also not significant (p-value: 0.065)</p></div><div><h3>Conclusions</h3><p>The aggressive nature of PUCR results in a rapid deterioration regardless of the treatment modality chosen. Surgery even in resectable patients doesn't carry a significant survival benefit. Chemotherapy should remain the mainstay of therapy for this patient cohort.</p></div>","PeriodicalId":100278,"journal":{"name":"Clinical Surgical Oncology","volume":"3 1","pages":"Article 100033"},"PeriodicalIF":0.0,"publicationDate":"2024-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2773160X24000011/pdfft?md5=c9b34149f131eae0606f533d4882a553&pid=1-s2.0-S2773160X24000011-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139395146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of diverting stoma on long-term survival in patients with rectal cancer: A nationwide study based on health insurance claims data","authors":"Nobuaki Hoshino ,&nbsp;Koya Hida ,&nbsp;Yudai Fukui ,&nbsp;Yoshimitsu Takahashi ,&nbsp;Takeo Nakayama ,&nbsp;Kazutaka Obama","doi":"10.1016/j.cson.2023.100030","DOIUrl":"https://doi.org/10.1016/j.cson.2023.100030","url":null,"abstract":"<div><h3>Background</h3><p>A diverting stoma is often created to prevent anastomotic leakage when a low anterior resection (LAR) is performed for rectal cancer. However, it remains unclear how a diverting stoma impacts the prognosis.</p></div><div><h3>Methods</h3><p>We identified patients with rectal cancer in the National Database of Health Insurance Claims and Specific Health Checkups of Japan who underwent LAR in 2014 and received adjuvant chemotherapy within 12 months of surgery. Overall survival was compared according to the presence or absence of a diverting stoma. Only patients with a stoma were selected to compare overall survival according to the timing of stoma closure.</p></div><div><h3>Results</h3><p>Patients with a diverting stoma had a significantly better prognosis than those without a diverting stoma (hazard ratio [HR] 0.79, 95% confidence interval [CI] 0.63–0.99, <em>P</em> ​= ​0.039). Compared with patients with early closure, the prognosis of patients with late closure was significantly better (HR 0.56, 95% CI 0.33–0.95, <em>P</em> ​= ​0.031) and that of patients without stoma closure was significantly poorer (HR 2.21, 95% CI 1.34–3.64, <em>P</em> ​= ​0.002).</p></div><div><h3>Conclusion</h3><p>Among patients with rectal cancer who underwent LAR followed by adjuvant chemotherapy, those who had a diverting stoma had better prognosis than those who did not. Patients with a diverting stoma who underwent late closure had the best prognosis.</p></div>","PeriodicalId":100278,"journal":{"name":"Clinical Surgical Oncology","volume":"2 4","pages":"Article 100030"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2773160X23000223/pdfft?md5=2cb2b9b3a9f749bae1e0af83a2c747c4&pid=1-s2.0-S2773160X23000223-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138465854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low axillary sampling to stage post neoadjuvant axilla in breast cancer patients - A practical approach in developing world","authors":"Abinaya R.N ,&nbsp;Kurian Cherian ,&nbsp;Rexeena Bhargavan ,&nbsp;Aleyamma Mathew ,&nbsp;Paul Augustine","doi":"10.1016/j.cson.2023.100029","DOIUrl":"https://doi.org/10.1016/j.cson.2023.100029","url":null,"abstract":"<div><h3>Background</h3><p>Post-neoadjuvant sentinel lymph node biopsy or targeted axillary dissection in carcinoma breast patients need costly infrastructure, making it out of reach for resource constrained developing countries. This study assesses the diagnostic accuracy of low axillary node sampling to predict the nodal status of the post-chemotherapy node-negative axilla.</p></div><div><h3>Materials and methods</h3><p>This is a prospective study which included cytology proven node positive carcinoma breast patients who had node negative axilla after chemotherapy and underwent low axillary sampling with complete axillary lymph node dissection. Nodes below second intercostobrachial nerve were sent as low axillary sample.</p></div><div><h3>Results</h3><p>211 patients with carcinoma breast underwent FNAC of the axillary node prior to neoadjuvant systemic therapy (NAST). Low axillary sampling was performed on 77 patients who had clinically and radiologically node negative axilla after NAST. Out of 77, 24 (31%) had early breast cancer and 32 (41.5%) had T4 disease prior to NAST. In this cohort, 36 patients (47%) had a good biology tumour, 57 (74%) had Grade 3 tumour and 20 (26%) had lymphovascular invasion (LVI). Pathological complete response of breast and axilla was seen in 24 patients (31%). Low axillary sampling had a range of 1–12 nodes with median lymph nodal yield of 6. The false negative rate (FNR) of low axillary sampling was 8.3%. Good tumour biology, post NAST residual breast tumour and lymphovascular invasion were the independent predictors of positive low axillary nodes.</p></div><div><h3>Conclusions</h3><p>Low axillary sampling is an economical and feasible option to de-escalate axillary surgery with acceptable false negative rate in carcinoma breast patients who had node negative axilla post neoadjuvant systemic therapy.</p></div>","PeriodicalId":100278,"journal":{"name":"Clinical Surgical Oncology","volume":"2 4","pages":"Article 100029"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2773160X23000211/pdfft?md5=abd50a9b0257c4f00e3e5a29b1b71f47&pid=1-s2.0-S2773160X23000211-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138474031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microsatellite instability in gastric cancer: An institutional case series analysis in patients treated with neoadjuvant therapy","authors":"Laura Lorenzon,&nbsp;Alberto Biondi,&nbsp;Gloria Santoro,&nbsp;Annamaria Agnes,&nbsp;Antonio Laurino,&nbsp;Antonia Strippoli,&nbsp;Riccardo Ricci,&nbsp;Roberto Persiani,&nbsp;Domenico D'Ugo","doi":"10.1016/j.cson.2023.100031","DOIUrl":"https://doi.org/10.1016/j.cson.2023.100031","url":null,"abstract":"<div><h3>Introduction</h3><p>Past studies documented that microsatellite instability (MSI) is associated with improved survival in gastric cancer (GC). The aim of this study was to evaluate MSI status in a series of GCs treated with neoadjuvant therapy in relation to the tumors' characteristics and oncological outcomes.</p></div><div><h3>Methods</h3><p>Patients with GCs treated between 2017 and 2022 ​at a single Italian high-volume Institution undergoing pre-operative treatment followed by resection were included if studied for their microsatellite status. Clinicopathological data were analyzed for the association with MSI. The same features were analyzing pooling the series with a subset of patients from another European trial.</p><p>Secondary outcomes included the overall (OS), and disease-free (DFS) survivals comparing MSI <em>vs</em> microsatellite stable (MSS) GCs, and GCs presenting complete-major response (TRG1-2) <em>vs</em> partial response (TRG3-4) and absence of response (TRG5).</p></div><div><h3>Results</h3><p>Among 73 patients selected, 12.3% were MSI. In the single institutional analysis, we documented a difference in the distribution of ypT stages with a prevalence of ypT0 patients in MSI <em>vs</em> MSS patients (ypT0 respectively 11.1% vs 1.6%, p ​&lt; ​0.0001). However, this difference was not of statistical value when pooling patients with those from the European trial (overall 108 patients, 9.2% MSI; ypT0 respectively 10.0% <em>vs</em> 2.0%, p 0.144). In the pooled analysis, a prevalence of female patients was reported in the MSI group comparing MSS (respectively, 70.0% <em>vs</em> 27.6%, p 0.01). At a mean follow-up of 27.7 months, OS and DFS survivals were reported similar comparing MSS and MSI (log-rank test respectively p 0.18 and p 0.96), however TRG1-2 ​GCs had improved OS and DFS comparing other sub-groups (TRG1-2 <em>vs</em> TRG3-4 <em>vs</em> TRG5, OS and DFS log-rank test respectively p 0.017 and p 0.0029).</p></div><div><h3>Conclusion</h3><p>This study could not demonstrate a correlation between microsatellite status and survival in gastric cancer patients who underwent pre-operative treatment. A complete/major response was the only variable correlated with mid-term survival.</p></div>","PeriodicalId":100278,"journal":{"name":"Clinical Surgical Oncology","volume":"3 1","pages":"Article 100031"},"PeriodicalIF":0.0,"publicationDate":"2023-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2773160X23000235/pdfft?md5=50f1d3d1c0e2bdacc97c4552e00380f1&pid=1-s2.0-S2773160X23000235-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138557583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}